Entrada de Pandipedia
Actualitzat el 21 Nov 202612 fontsExplora Pandipedia
Informe de recerca

Why can't people get estradiol patches?

The FDA's explanation is that demand has risen faster than supply: particular brands and strengths run out at particular pharmacies while patches as a whole are still being shipped.[1] That is also why two lists disagree. The FDA has not declared a shortage and says patches “remain available”.[2] The pharmacists' society ASHP has listed a shortage since 30 January 2026 and now counts 24 of 46 packs as affected.[3]

Last updated: 20 November 2026. This page reports supply status and sources only. It is not medical advice.

Where you lookWhat it shows on 20 Nov 2026
FDA Drug Shortages database0 entries for estradiol, current or resolved[4]
Pharmacists' list (ASHP): packs listed as affected 24 of 46[5]
Pharmacists' list (ASHP): packs listed as available 22 of 46[6]
Companies with at least one affected pack5 of 6[7]

A “pack” here is one brand, strength and pack size with its own product code. Counts are ours, from the ASHP bulletin dated 4 November 2026.[8]

What we know

  • The FDA has not declared a shortage. Its database has no estradiol entry.[9] On 3 September it said that “availability of certain products or brands may vary by pharmacy or location”.[10] On 30 October the health department said the FDA “is not aware of an imminent risk of a nationwide shortage” and described “localized challenges”.[11]
  • The pharmacists' list says otherwise. ASHP lists 24 packs from 5 companies as affected. All 22 packs it lists as available come from two companies: Mylan (Viatris) with 16 and Amneal with 6.[12]
  • The stated cause is demand. The FDA says demand rose after it asked companies in November 2025 to remove boxed warnings from menopause hormone therapy labels.[13][14] A Sandoz spokesperson told Reuters in April that this “created unprecedented demand that cannot fully be met at present”.[15]
  • Supply has grown, but factories are slow to expand. The FDA says supply “has nearly doubled” in a year, and that larger expansions take time because patches need specialised equipment.[16]

The ledger: product by product

One row per product line in the ASHP bulletin of 4 November 2026.[17] None of these products is on the FDA shortage list.[18] Strengths are the labelled release rates. The status terms (back order, on allocation) are ASHP's.

ProductListed as affectedListed as availableReason and expected date
Climara (Bayer)
once-weekly
All 6 strengthsNoneNo reason given to ASHP. Intermittent back order; released as it becomes available.
Estradiol patch (Sandoz)
once-weekly
All 6 strengthsNoneNo reason given to ASHP. 0.0375 mg/24 hour on back order with no date; the rest on allocation.
Estradiol patch (Mylan, a Viatris company)
4-count packs
NoneAll 6 strengthsListed as available.
Dotti (Amneal)
twice-weekly
0.0375 mg/24 hour4 other strengthsNo reason given to ASHP. Back order; the company cannot estimate a release date.
Lyllana (Amneal)
twice-weekly
0.025, 0.05 and 0.1 mg/24 hour0.0375 and 0.075 mg/24 hourNo reason given to ASHP. Back order with no date.
Estradiol patch (Noven, sold via Grove)
twice-weekly
All 5 strengthsNoneIncreased demand. Intermittent back order, with weekly releases.
Estradiol patch (Zydus)
twice-weekly
0.05, 0.075 and 0.1 mg/24 hourNone listedNo reason given to ASHP. 0.05 and 0.1: back order, release estimated for early November 2026. 0.075: on allocation.
Estradiol patch (Mylan, a Viatris company)
8-count packs
NoneAll 10 packs (5 strengths)Listed as available.

FDA's Orange Book lists six companies with approved prescription estradiol-only patches: Amneal, Bayer, Mylan, Noven, Sandoz and Zydus.[19] The FDA says it is working with “all six manufacturers” but does not name them.[20] Three brands in the Orange Book are in neither ASHP list: Vivelle-Dot (Sandoz), Menostar (Bayer) and Minivelle (Noven).[21] ASHP says Minivelle was discontinued in February.[22]

How “no shortage” and “my pharmacy can't fill it” are both true

The two lists measure different things. This table quotes a comparison written jointly by the FDA, ASHP and the University of Utah, and the FDA's own FAQ.

QuestionFDAASHP
What counts as a shortage“on a nationwide level, supply is not meeting current demand”[23]Verified with manufacturers, and it “affects how pharmacy prepares or dispenses a product”[24]
Whose view it reflects“shortage status at drug firm level”[25]“status at healthcare provider level”[26]
When it ends“One or more manufacturers are in production and able to meet full market demand”[27]“All manufacturers of the drug restore all formulations and dosage sizes to full availability”[28]

The FDA adds up all approved patches from all makers across the country. Its database says a market is covered when one manufacturer can meet total demand, and that even then “some manufacturers may not have all presentations available”.[29] ASHP lists a product while any maker has a gap in any strength, and notes that it “frequently lists more shortages than FDA”.[30] A prescription is for one product and one strength, which is the level ASHP tracks.

Where the records conflict

  • Inside the ASHP bulletin. One section says “Lyllana is currently available”; another says three Lyllana strengths are on back order. It also refers to a shortage of Viatris twice-weekly patches while listing every Viatris pack as available.[31]
  • How many products. A letter from eight members of Congress dated 31 July put ASHP's count at 14 “brands or dosages”.[32] The 4 November bulletin lists 24.[33] We could not read earlier versions, so the trend is unconfirmed.
  • How much demand grew. No official figure exists. The letter cites Epic Research: prescriptions up 72% between 2021 and autumn 2025.[34] Reuters cites Truveta: use up 184% since 2023.[35] We did not read either dataset.

Outside the US: Australia's regulator lists a shortage of estradiol patches after notices from Sandoz and Juno. It calls the shortage “global” and expects four Estradot strengths back by 30 June 2027.[36]

What is still unknown

  • The numbers behind the FDA's view. It has published no supply or demand figures for patches.
  • Why four of the five affected companies have gaps. Only Noven gave ASHP a reason.[37]
  • When it ends. No official source gives a date. Zydus's early-November estimate has not been confirmed.[38]
  • Whether the FDA has answered Congress. The House letter asked seven questions.[39] A local news report says three senators asked on 20 October what it would take to list the patches, with answers due 16 November.[40] We found no published reply.

What would settle it

  • FDA figures for patches shipped and prescriptions written, by month.
  • The FDA's written answers to the two congressional letters.
  • The next ASHP update, and any dated release notice from a manufacturer.

How this page was made

Every source was opened and read on 20 November 2026. Counts come from a script run over saved copies of the ASHP bulletin, the Orange Book product file and the FDA shortage download (1,579 rows, 224 drug names, none containing “estradiol”).[41][42] The FDA's public data service gave the same result. We found no supply statement on any manufacturer's own website; the company positions here are as reported to ASHP or Reuters. The senators' letter was read only in a news report.[43] Left out: pharmacy-level anecdotes, clinic blogs, survey results, and any guidance on treatment. Canadian and UK regulators were not checked. For questions about a prescription, the FDA points patients to their pharmacist or prescriber.[44]

Continua explorant
Mostra-ho tot